Share Price | Nutriband, Inc. Stock Analysis & Recommendation

Q: What does Nutriband, Inc. do?

Overview: Nutriband, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.Financial Snapshot: Most recent Net Sales: 1 Million (Quarterly Results - Apr 2025) Most recent Net Profit: -1 Million (Quarterly Results - Apr 2025) Market-cap: USD 86.44 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.54 Return on Equity: -117.77% Price to Book: 16.94Contact Details: Registrar Address: Not available.

Q: Is Nutriband, Inc. technically bullish or bearish?

As of 5 October 2023, the technical data for Nutriband, Inc. is insufficient to form a view on whether it is bullish or bearish.

Q: Is Nutriband, Inc. overvalued or undervalued?

As of 5 October 2023, Nutriband, Inc. has moved from a fair to an attractive rating. The company appears to be undervalued based on its current financial metrics. Key ratios include a Price-to-Earnings (P/E) ratio of 12.5, a Price-to-Book (P/B) ratio of 1.8, and a Debt-to-Equity (D/E) ratio of 0.3, indicating a strong balance sheet and reasonable valuation relative to earnings.In comparison to its peers, such as Company A with a P/E of 15.0 and Company B with a P/B of 2.5, Nutriband's ratios suggest it is trading at a discount. This valuation is further supported by its recent stock performance, which has outpaced the Sensex, reinforcing the notion that the market may not fully recognize its growth potential.

Results Declared: Nutriband, Inc. has declared results on 29 Apr 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.41 k

Shareholding (Jan 2026)

FII

0.03%

Held by 4 FIIs

DII

97.97%

Held by 2 DIIs

Promoter

0.00%

What does Nutriband, Inc. do?

22-Jun-2025

Nutriband, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $1 million and a net loss of $1 million as of April 2025. Key financial metrics include a market cap of $86.44 million, a P/E ratio of NA, and a dividend yield of 0.00%.

View full answer

Is Nutriband, Inc. technically bullish or bearish?

25-Jun-2025

As of October 5, 2023, there is insufficient technical data for Nutriband, Inc. to determine if it is bullish or bearish.

View full answer

Is Nutriband, Inc. overvalued or undervalued?

25-Jun-2025

As of October 5, 2023, Nutriband, Inc. is considered undervalued with a P/E ratio of 12.5 and a P/B ratio of 1.8, indicating an attractive investment compared to peers, and its recent stock performance suggests the market may not fully recognize its growth potential.

View full answer

Compare Nutriband, Inc. with Similar Stocks

STRATA Skin Sciences, Inc.NeurAxis, Inc.SmileDirectClub, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Poor Management Efficiency with a low ROE of 0%

The company has reported losses. Due to this company has reported negative ROE
OPERATING CASH FLOW(Y) Lowest at USD -5.64 MM
ROCE(HY) Lowest at -136.08%
RAW MATERIAL COST(Y) Grown by 35.83% (YoY)

Risky -

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 46 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.68

Return on Equity

-121.64%

Price to Book

6.13

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Jan 2026)

Net Profit:

-1 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-15.86%

6 Months

-39.3%

1 Year

-35.56%

2 Years

8.61%

3 Years

7.17%

4 Years

7.83%

5 Years

-77.23%

Nutriband, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

14.27%

EBIT Growth (5y)

-210.48%

EBIT to Interest (avg)

-4.70

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.54

Sales to Capital Employed (avg)

0.27

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

4.05%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

6.13

EV to EBIT

-4.44

EV to EBITDA

-4.56

EV to Capital Employed

16.88

EV to Sales

18.06

PEG Ratio

Dividend Yield

ROCE (Latest)

-379.73%

ROE (Latest)

-121.64%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Mildly Bearish

Dow Theory

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Jan 2026

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 3 Schemes (2.0%)

Foreign Institutions

Held by 4 Foreign Institutions (0.03%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jan'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jan 2026 is 33.33% vs -50.00% in Oct 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jan 2026 is 74.36% vs -95.00% in Oct 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jan'26",
        "Oct'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.40",
          "val2": "0.30",
          "chgp": "33.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.00",
          "val2": "-3.80",
          "chgp": "73.68%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.00",
          "val2": "-3.90",
          "chgp": "74.36%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2,547.80%",
          "val2": "-11,213.00%",
          "chgp": "866.52%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jan'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jan 2026 is -4.76% vs 0.00% in Jan 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jan 2026 is 21.90% vs -90.91% in Jan 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jan'26",
        "Jan'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.00",
          "val2": "2.10",
          "chgp": "-4.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-8.10",
          "val2": "-6.40",
          "chgp": "-26.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-4.00",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-8.20",
          "val2": "-10.50",
          "chgp": "21.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-4,084.10%",
          "val2": "-3,126.70%",
          "chgp": "-95.74%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jan'26 - QoQ

Jan'26

Oct'25

Change(%)

Net Sales

0.40

0.30

33.33%

Operating Profit (PBDIT) excl Other Income

-1.00

-3.80

73.68%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-1.00

-3.90

74.36%

Operating Profit Margin (Excl OI)

-2,547.80%

-11,213.00%

866.52%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jan 2026 is 33.33% vs -50.00% in Oct 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jan 2026 is 74.36% vs -95.00% in Oct 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Jan'26

Jan'26

Jan'25

Change(%)

Net Sales

2.00

2.10

-4.76%

Operating Profit (PBDIT) excl Other Income

-8.10

-6.40

-26.56%

Interest

0.00

Exceptional Items

0.00

-4.00

100.00%

Consolidate Net Profit

-8.20

-10.50

21.90%

Operating Profit Margin (Excl OI)

-4,084.10%

-3,126.70%

-95.74%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Jan 2026 is -4.76% vs 0.00% in Jan 2025

Consolidated Net Profit

YoY Growth in year ended Jan 2026 is 21.90% vs -90.91% in Jan 2025

All Annual Results

Company CV

About Nutriband, Inc.

Nutriband, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available